LPOXY Therapeutics is working to solve a $6 billion healthcare problem with no approved preventive solutions available.
Patients – Half a million Americans will get antibiotic-induced C. difficile colitis this year and 30,000 will die
Current Preventive Options – No approved therapies currently for the prevention of primary infections
Annual US Healthcare Cost of C. difficile – $6+ billion
Public Health Status – CDC designated urgent public health threat
Therapy Targeting Strategy – Co-administered with high-risk antibiotics
Therapy Course Frequency – Repeatable with each high-risk antibiotic exposure
Our patented therapy, SIDIPREV™, is moving towards pivotal clinical trials in 2026.
With successful clinical validation, SIDIPREV™ could become the new standard of care for C. difficile prevention — delivering high clinical impact to address this unmet need.
Hospitals face substantial financial penalties and unreimbursed costs from C. difficile infections. SIDIPREV™ offers cost-efficiency for hospitals — significantly reducing infection-related losses.
With no vaccine hesitancy, no antimicrobial stewardship barriers, and no competing prevention therapies, SIDIPREV™ is uniquely positioned for rapid adoption and scalable market penetration.
Strategic Partnerships & Asset Acquisition
In 2025, LPOXY secured previously generated clinical and regulatory assets that de-risk development and expedite initiation of our pivotal trial in C. difficile prevention.
Robust Intellectual Property Protection
SIDIPREV™ is protected by a portfolio of issued patents in major global markets, securing long-term exclusivity and market value.
Efficient Development Pathway
LPOXY plans to initiate a pivotal Phase II study for SIDIPREV™ under the Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacterial and Antifungal Development (LPAD).
The LPAD pathway is designed to expedite the development of therapies for serious, life-threatening infections in limited populations with unmet medical needs. C. difficile has been identified by the Centers for Disease Control and Prevention (CDC) as an urgent public health threat, contributing to more than 80 American deaths each day.
Our targeted regulatory pathway leverages existing safety data and clinical precedence for oxygen therapeutics, significantly reducing development risk and time.
Capital Raise: Pivotal Trial Execution
LPOXY is raising capital to execute our pivotal clinical trial under the FDA’s LPAD pathway.
We are assembling a syndicate of strategic investors to enable trial initiation in 2026 and drive value-creation milestones through NDA filing by 2029.